Global Liposomal-based Drug market size is predicted to grow from US$ 6466 million in 2025 to US$ 11690 million in 2031; it is expected to grow at a CAGR of 10.4% from 2025 to 2031. Get Access Now!

Global Liposomal-based Drug Market Growth Status and Outlook 2025-2031

The global Liposomal-based Drug market size is predicted to grow from US$ 6466 million in 2025 to US$ 11690 million in 2031; it is expected to grow at a CAGR of 10.4% from 2025 to 2031. Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery. The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the markets potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs. LPI (LP Information) newest research report, the Liposomal-based Drug Industry Forecast looks at past sales and reviews total world Liposomal-based Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Liposomal-based Drug sales for 2025 through 2031. With Liposomal-based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomal-based Drug industry. This Insight Report provides a comprehensive analysis of the global Liposomal-based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Liposomal-based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Liposomal-based Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomal-based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomal-based Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal-based Drug market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Liposomes Drugs &nbsp;&nbsp;&nbsp; Lipid Nanoparticle Drugs Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Retail Pharmacy &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Sun Pharmaceutical &nbsp;&nbsp;&nbsp; CSPC &nbsp;&nbsp;&nbsp; Kinyond &nbsp;&nbsp;&nbsp; Teva &nbsp;&nbsp;&nbsp; Fudan-Zhangjiang &nbsp;&nbsp;&nbsp; Zydus Cadila &nbsp;&nbsp;&nbsp; TTY Biopharma &nbsp;&nbsp;&nbsp; Pacira &nbsp;&nbsp;&nbsp; Luye Pharma &nbsp;&nbsp;&nbsp; Leadiant Biosciences &nbsp;&nbsp;&nbsp; Ipsen &nbsp;&nbsp;&nbsp; Sayre Therapeutics &nbsp;&nbsp;&nbsp; Jazz &nbsp;&nbsp;&nbsp; Alnylam &nbsp;&nbsp;&nbsp; Bausch Health &nbsp;&nbsp;&nbsp; Acrotech Biopharma &nbsp;&nbsp;&nbsp; Takeda &nbsp;&nbsp;&nbsp; Chiesi Farmaceutici &nbsp;&nbsp;&nbsp; Gilead Sciences

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Liposomal-based Drug Market Size (2020-2031) &nbsp;2.1.2 Liposomal-based Drug Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Liposomal-based Drug by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Liposomal-based Drug Segment by Type &nbsp;2.2.1 Liposomes Drugs &nbsp;2.2.2 Lipid Nanoparticle Drugs &nbsp;2.3 Liposomal-based Drug Market Size by Type &nbsp;2.3.1 Liposomal-based Drug Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Liposomal-based Drug Market Size Market Share by Type (2020-2025) &nbsp;2.4 Liposomal-based Drug Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Retail Pharmacy &nbsp;2.4.3 Other &nbsp;2.5 Liposomal-based Drug Market Size by Application &nbsp;2.5.1 Liposomal-based Drug Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Liposomal-based Drug Market Size Market Share by Application (2020-2025) 3 Liposomal-based Drug Market Size by Player &nbsp;3.1 Liposomal-based Drug Market Size Market Share by Player &nbsp;3.1.1 Global Liposomal-based Drug Revenue by Player (2020-2025) &nbsp;3.1.2 Global Liposomal-based Drug Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Liposomal-based Drug Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Liposomal-based Drug by Region &nbsp;4.1 Liposomal-based Drug Market Size by Region (2020-2025) &nbsp;4.2 Global Liposomal-based Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Liposomal-based Drug Market Size Growth (2020-2025) &nbsp;4.4 APAC Liposomal-based Drug Market Size Growth (2020-2025) &nbsp;4.5 Europe Liposomal-based Drug Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Liposomal-based Drug Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Liposomal-based Drug Market Size by Country (2020-2025) &nbsp;5.2 Americas Liposomal-based Drug Market Size by Type (2020-2025) &nbsp;5.3 Americas Liposomal-based Drug Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Liposomal-based Drug Market Size by Region (2020-2025) &nbsp;6.2 APAC Liposomal-based Drug Market Size by Type (2020-2025) &nbsp;6.3 APAC Liposomal-based Drug Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Liposomal-based Drug Market Size by Country (2020-2025) &nbsp;7.2 Europe Liposomal-based Drug Market Size by Type (2020-2025) &nbsp;7.3 Europe Liposomal-based Drug Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Liposomal-based Drug by Region (2020-2025) &nbsp;8.2 Middle East & Africa Liposomal-based Drug Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Liposomal-based Drug Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Liposomal-based Drug Market Forecast &nbsp;10.1 Global Liposomal-based Drug Forecast by Region (2026-2031) &nbsp;10.1.1 Global Liposomal-based Drug Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Liposomal-based Drug Forecast &nbsp;10.1.3 APAC Liposomal-based Drug Forecast &nbsp;10.1.4 Europe Liposomal-based Drug Forecast &nbsp;10.1.5 Middle East & Africa Liposomal-based Drug Forecast &nbsp;10.2 Americas Liposomal-based Drug Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Liposomal-based Drug Forecast &nbsp;10.2.2 Canada Market Liposomal-based Drug Forecast &nbsp;10.2.3 Mexico Market Liposomal-based Drug Forecast &nbsp;10.2.4 Brazil Market Liposomal-based Drug Forecast &nbsp;10.3 APAC Liposomal-based Drug Forecast by Region (2026-2031) &nbsp;10.3.1 China Liposomal-based Drug Market Forecast &nbsp;10.3.2 Japan Market Liposomal-based Drug Forecast &nbsp;10.3.3 Korea Market Liposomal-based Drug Forecast &nbsp;10.3.4 Southeast Asia Market Liposomal-based Drug Forecast &nbsp;10.3.5 India Market Liposomal-based Drug Forecast &nbsp;10.3.6 Australia Market Liposomal-based Drug Forecast &nbsp;10.4 Europe Liposomal-based Drug Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Liposomal-based Drug Forecast &nbsp;10.4.2 France Market Liposomal-based Drug Forecast &nbsp;10.4.3 UK Market Liposomal-based Drug Forecast &nbsp;10.4.4 Italy Market Liposomal-based Drug Forecast &nbsp;10.4.5 Russia Market Liposomal-based Drug Forecast &nbsp;10.5 Middle East & Africa Liposomal-based Drug Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Liposomal-based Drug Forecast &nbsp;10.5.2 South Africa Market Liposomal-based Drug Forecast &nbsp;10.5.3 Israel Market Liposomal-based Drug Forecast &nbsp;10.5.4 Turkey Market Liposomal-based Drug Forecast &nbsp;10.6 Global Liposomal-based Drug Forecast by Type (2026-2031) &nbsp;10.7 Global Liposomal-based Drug Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Liposomal-based Drug Forecast 11 Key Players Analysis &nbsp;11.1 Johnson & Johnson &nbsp;11.1.1 Johnson & Johnson Company Information &nbsp;11.1.2 Johnson & Johnson Liposomal-based Drug Product Offered &nbsp;11.1.3 Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Johnson & Johnson Main Business Overview &nbsp;11.1.5 Johnson & Johnson Latest Developments &nbsp;11.2 Sun Pharmaceutical &nbsp;11.2.1 Sun Pharmaceutical Company Information &nbsp;11.2.2 Sun Pharmaceutical Liposomal-based Drug Product Offered &nbsp;11.2.3 Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Sun Pharmaceutical Main Business Overview &nbsp;11.2.5 Sun Pharmaceutical Latest Developments &nbsp;11.3 CSPC &nbsp;11.3.1 CSPC Company Information &nbsp;11.3.2 CSPC Liposomal-based Drug Product Offered &nbsp;11.3.3 CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 CSPC Main Business Overview &nbsp;11.3.5 CSPC Latest Developments &nbsp;11.4 Kinyond &nbsp;11.4.1 Kinyond Company Information &nbsp;11.4.2 Kinyond Liposomal-based Drug Product Offered &nbsp;11.4.3 Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Kinyond Main Business Overview &nbsp;11.4.5 Kinyond Latest Developments &nbsp;11.5 Teva &nbsp;11.5.1 Teva Company Information &nbsp;11.5.2 Teva Liposomal-based Drug Product Offered &nbsp;11.5.3 Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Teva Main Business Overview &nbsp;11.5.5 Teva Latest Developments &nbsp;11.6 Fudan-Zhangjiang &nbsp;11.6.1 Fudan-Zhangjiang Company Information &nbsp;11.6.2 Fudan-Zhangjiang Liposomal-based Drug Product Offered &nbsp;11.6.3 Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Fudan-Zhangjiang Main Business Overview &nbsp;11.6.5 Fudan-Zhangjiang Latest Developments &nbsp;11.7 Zydus Cadila &nbsp;11.7.1 Zydus Cadila Company Information &nbsp;11.7.2 Zydus Cadila Liposomal-based Drug Product Offered &nbsp;11.7.3 Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Zydus Cadila Main Business Overview &nbsp;11.7.5 Zydus Cadila Latest Developments &nbsp;11.8 TTY Biopharma &nbsp;11.8.1 TTY Biopharma Company Information &nbsp;11.8.2 TTY Biopharma Liposomal-based Drug Product Offered &nbsp;11.8.3 TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 TTY Biopharma Main Business Overview &nbsp;11.8.5 TTY Biopharma Latest Developments &nbsp;11.9 Pacira &nbsp;11.9.1 Pacira Company Information &nbsp;11.9.2 Pacira Liposomal-based Drug Product Offered &nbsp;11.9.3 Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Pacira Main Business Overview &nbsp;11.9.5 Pacira Latest Developments &nbsp;11.10 Luye Pharma &nbsp;11.10.1 Luye Pharma Company Information &nbsp;11.10.2 Luye Pharma Liposomal-based Drug Product Offered &nbsp;11.10.3 Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Luye Pharma Main Business Overview &nbsp;11.10.5 Luye Pharma Latest Developments &nbsp;11.11 Leadiant Biosciences &nbsp;11.11.1 Leadiant Biosciences Company Information &nbsp;11.11.2 Leadiant Biosciences Liposomal-based Drug Product Offered &nbsp;11.11.3 Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Leadiant Biosciences Main Business Overview &nbsp;11.11.5 Leadiant Biosciences Latest Developments &nbsp;11.12 Ipsen &nbsp;11.12.1 Ipsen Company Information &nbsp;11.12.2 Ipsen Liposomal-based Drug Product Offered &nbsp;11.12.3 Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Ipsen Main Business Overview &nbsp;11.12.5 Ipsen Latest Developments &nbsp;11.13 Sayre Therapeutics &nbsp;11.13.1 Sayre Therapeutics Company Information &nbsp;11.13.2 Sayre Therapeutics Liposomal-based Drug Product Offered &nbsp;11.13.3 Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 Sayre Therapeutics Main Business Overview &nbsp;11.13.5 Sayre Therapeutics Latest Developments &nbsp;11.14 Jazz &nbsp;11.14.1 Jazz Company Information &nbsp;11.14.2 Jazz Liposomal-based Drug Product Offered &nbsp;11.14.3 Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.14.4 Jazz Main Business Overview &nbsp;11.14.5 Jazz Latest Developments &nbsp;11.15 Alnylam &nbsp;11.15.1 Alnylam Company Information &nbsp;11.15.2 Alnylam Liposomal-based Drug Product Offered &nbsp;11.15.3 Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.15.4 Alnylam Main Business Overview &nbsp;11.15.5 Alnylam Latest Developments &nbsp;11.16 Bausch Health &nbsp;11.16.1 Bausch Health Company Information &nbsp;11.16.2 Bausch Health Liposomal-based Drug Product Offered &nbsp;11.16.3 Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.16.4 Bausch Health Main Business Overview &nbsp;11.16.5 Bausch Health Latest Developments &nbsp;11.17 Acrotech Biopharma &nbsp;11.17.1 Acrotech Biopharma Company Information &nbsp;11.17.2 Acrotech Biopharma Liposomal-based Drug Product Offered &nbsp;11.17.3 Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.17.4 Acrotech Biopharma Main Business Overview &nbsp;11.17.5 Acrotech Biopharma Latest Developments &nbsp;11.18 Takeda &nbsp;11.18.1 Takeda Company Information &nbsp;11.18.2 Takeda Liposomal-based Drug Product Offered &nbsp;11.18.3 Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.18.4 Takeda Main Business Overview &nbsp;11.18.5 Takeda Latest Developments &nbsp;11.19 Chiesi Farmaceutici &nbsp;11.19.1 Chiesi Farmaceutici Company Information &nbsp;11.19.2 Chiesi Farmaceutici Liposomal-based Drug Product Offered &nbsp;11.19.3 Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.19.4 Chiesi Farmaceutici Main Business Overview &nbsp;11.19.5 Chiesi Farmaceutici Latest Developments &nbsp;11.20 Gilead Sciences &nbsp;11.20.1 Gilead Sciences Company Information &nbsp;11.20.2 Gilead Sciences Liposomal-based Drug Product Offered &nbsp;11.20.3 Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.20.4 Gilead Sciences Main Business Overview &nbsp;11.20.5 Gilead Sciences Latest Developments 12 Research Findings and Conclusion

Report	Global Liposomal-based Drug Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI35785

Buyer Information

Order Summary